<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03643172</url>
  </required_header>
  <id_info>
    <org_study_id>2</org_study_id>
    <nct_id>NCT03643172</nct_id>
  </id_info>
  <brief_title>Terminator 2 Register</brief_title>
  <official_title>Termination of Nucleos(t)Ide Analogue Therapy of HBeAg Negative Chronic Hepatitis B - 2nd Register Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Center for Infection Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      All patients with chronic HBeAg negative hepatitis B treated with nucleos(t)ide analogues,
      who discontinue treatment based in the criteria outlined in the EASL hepatitis B guidelines
      shall be included in the present study. The aim is to evaluate the clinical outcome
      (virological relapse, HBsAg decline) and associated virological and immunological parameters.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HBsAg</measure>
    <time_frame>48 weeks</time_frame>
    <description>HBsAg Change &gt; 1 log 48 weeks after stopping NA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virological relapse</measure>
    <time_frame>at every visit up to 96 weeks</time_frame>
    <description>HBV DNA &gt; 2,000 IU/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical relapse</measure>
    <time_frame>at every visit up to 96 weeks</time_frame>
    <description>ALT &gt; 2 x upper limit of normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retreatment</measure>
    <time_frame>at every visit up to 48 weeks</time_frame>
    <description>Retreatment until week 48 according to current EASL guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negativity for HBsAg</measure>
    <time_frame>at every visit up to 96 weeks</time_frame>
    <description>HBsAg negative until week 96 of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>timepoint of relapse</measure>
    <time_frame>at every visit up to 96 weeks</time_frame>
    <description>timepoint of relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T cell response</measure>
    <time_frame>at every visit up to 96 weeks</time_frame>
    <description>&gt; 3x change of T cell responses from baseline after in vitro culture with HBV specific peptides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine response</measure>
    <time_frame>at every visit up to 96 weeks</time_frame>
    <description>&gt; 3x change of cytokines from baseline measured by ELISA and Multiplex assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chance in HBcrAg</measure>
    <time_frame>at every visit up to 96 weeks</time_frame>
    <description>Chance in HBcrAg (U/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HBV RNA</measure>
    <time_frame>at every visit up to 96 weeks</time_frame>
    <description>Chance in HBV RNA (U/mL)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Hepatitis B, HBeAg Negative</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. Non-cirrhotic male and female patients with chronic hepatitis B virus infection
             documented by detectable HBsAg.

          2. Age &gt; 18 years

          3. ongoing antiviral therapy with Entecavir or Tenofovir (TDF)

          4. At least 3 years HBV-DNA &lt; 20 IU/ml (=100 copies/ml)

          5. HBeAg negative
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients with chronic hepatitis B virus infection documented by
             detectable HBsAg.

          2. Age &gt; 18 years

          3. Ongoing antiviral therapy with Entecavir or Tenofovir (TDF)

          4. At least 3 years HBV-DNA &lt; 20 IU/ml (=100 copies/ml)

          5. HBeAg negative

          6. Willingness to give written informed consent and willingness to participate and to
             comply with the protocol.

        Exclusion Criteria:

          1. HIV infection, persistent HDV-infection, persistent HCV infection

          2. History or other evidence of a medical condition associated with chronic liver disease
             other than HBV associated (e.g., hemochromatosis, autoimmune hepatitis, alcoholic
             liver disease, toxin exposures).

          3. History or other evidence of bleeding from esophageal varices or other conditions
             consistent with decompensated liver disease

          4. Patients with advanced liver fibrosis and liver cirrhosis (fibroscan &gt;10.0 kPa)

          5. Patients with hepatocellular carcinoma

          6. History of major organ transplantation or other immunosuppressive conditions

          7. History or other evidence of severe illness, malignancy or any other conditions which
             would make the patient, in the opinion of the investigator, unsuitable for the study

          8. History of any systemic anti-neoplastic or immunomodulatory treatment (including
             supraphysiologic doses of steroids and radiation) 12 months prior to cessation of
             antiviral therapy or the expectation that such treatment will be needed at any time
             during the study

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Markus Cornberg, MD, Prof</last_name>
    <phone>0049-511-532-6821</phone>
    <email>cornberg.markus@mh-hannover.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christoph Höner zu Siederdissen, MD</last_name>
    <email>hoenerzusiederdissen.christoph@mh-hannover.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxony</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Cornberg, MD</last_name>
      <email>cornberg.markus@mh-hannover.de</email>
    </contact>
    <contact_backup>
      <last_name>Christoph Höner zu Siederdissen, MD</last_name>
      <email>hoenerzusiederdissen.christoph@mh-hannover.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 19, 2018</study_first_submitted>
  <study_first_submitted_qc>August 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>February 22, 2019</last_update_submitted>
  <last_update_submitted_qc>February 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

